Mutation Analysis (MutSig 2CV v3.1)
Cholangiocarcinoma (Primary solid tumor)
21 August 2015 | analyses__2015_08_21
Maintainer Information
Citation Information
doi:10.7908/C10C4TXD
Maintained by David Heiman (Broad Institute)
Cite as Broad Institute TCGA Genome Data Analysis Center (2015): Mutation Analysis (MutSig 2CV v3.1). Broad Institute of MIT and Harvard. doi:10.7908/C10C4TXD
Overview
Introduction

This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig 2CV v3.1 was used to generate the results found in this report.

- Working with individual set: CHOL-TP

- Number of patients in set: 35

Input

The input for this pipeline is a set of individuals with the following files associated for each:

1. An annotated .maf file describing the mutations called for the respective individual, and their properties.

2. A .wig file that contains information about the coverage of the sample.

Summary

- MAF used for this analysis:CHOL-TP.final_analysis_set.maf

- Blacklist used for this analysis: pancan_mutation_blacklist.v14.hg19.txt

- Significantly mutated genes (q ≤ 0.1): 12

Results
Lego Plots

The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.

Figure 1. Get High-res Image SNV Mutation rate lego plot for entire set. Each bin is normalized by base coverage for that bin. Colors represent the six SNV types on the upper right. The three-base context for each mutation is labeled in the 4x4 legend on the lower right. The fractional breakdown of SNV counts is shown in the pie chart on the upper left. If this figure is blank, not enough information was provided in the MAF to generate it.

Figure 2. Get High-res Image SNV Mutation rate lego plots for 4 slices of mutation allele fraction (0<=AF<0.1, 0.1<=AF<0.25, 0.25<=AF<0.5, & 0.5<=AF) . The color code and three-base context legends are the same as the previous figure. If this figure is blank, not enough information was provided in the MAF to generate it.

CoMut Plot

Figure 3. Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.

Significantly Mutated Genes

Column Descriptions:

- nnon = number of (nonsilent) mutations in this gene across the individual set

- npat = number of patients (individuals) with at least one nonsilent mutation

- nsite = number of unique sites having a non-silent mutation

- nsil = number of silent mutations in this gene across the individual set

- p = p-value (overall)

- q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Table 1. Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 12. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).

rank | gene | longname | codelen | nnei | nncd | nsil | nmis | nstp | nspl | nind | nnon | npat | nsite | pCV | pCL | pFN | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | PBRM1 | polybromo 1 | 5417 | 23 | 0 | 0 | 0 | 6 | 0 | 2 | 8 | 8 | 8 | 2.6e-13 | 1 | 0.75 | 7.7e-12 | 1.4e-07
2 | HLA-B | major histocompatibility complex, class I, B | 1119 | 555 | 0 | 0 | 5 | 0 | 0 | 0 | 5 | 5 | 3 | 4e-07 | 0.0018 | 0.97 | 2e-08 | 0.00018
3 | MLL3 | myeloid/lymphoid or mixed-lineage leukemia 3 | 14968 | 3 | 0 | 0 | 2 | 4 | 1 | 0 | 7 | 7 | 4 | 0.000037 | 4e-05 | 0.99 | 5.3e-08 | 0.00032
4 | FTH1 | ferritin, heavy polypeptide 1 | 564 | 108 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 1 | 0.0002 | 0.001 | 0.078 | 3.2e-06 | 0.015
5 | TP53 | tumor protein p53 | 1889 | 60 | 0 | 0 | 4 | 0 | 0 | 2 | 6 | 5 | 6 | 4e-07 | 1 | 0.36 | 6.3e-06 | 0.023
6 | ARID1A | AT rich interactive domain 1A (SWI-like) | 6934 | 29 | 0 | 1 | 1 | 0 | 0 | 5 | 6 | 5 | 6 | 0.000025 | 1 | 0.025 | 0.000018 | 0.047
7 | DDHD1 | DDHD domain containing 1 | 2776 | 22 | 0 | 0 | 4 | 0 | 0 | 0 | 4 | 4 | 1 | 0.012 | 0.0001 | 1 | 0.000018 | 0.047
8 | MUC2 | mucin 2, oligomeric mucus/gel-forming | 8640 | 122 | 0 | 2 | 8 | 0 | 0 | 0 | 8 | 7 | 7 | 0.000077 | 0.034 | 0.62 | 0.000038 | 0.076
9 | IDH1 | isocitrate dehydrogenase 1 (NADP+), soluble | 1277 | 1000 | 0 | 0 | 4 | 0 | 0 | 0 | 4 | 4 | 1 | 0.00043 | 0.0066 | 0.94 | 0.000039 | 0.076
10 | MUC21 | mucin 21, cell surface associated | 1709 | 429 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 2 | 0.00034 | 0.0071 | 0.82 | 0.000042 | 0.076
11 | CLIP4 | CAP-GLY domain containing linker protein family, member 4 | 2178 | 128 | 0 | 0 | 2 | 1 | 0 | 1 | 4 | 4 | 4 | 4.1e-06 | 1 | 0.8 | 0.000054 | 0.088
12 | RUFY1 | RUN and FYVE domain containing 1 | 2195 | 14 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 0.000058 | NaN | NaN | 0.000058 | 0.088
13 | BAP1 | BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase) | 2254 | 8 | 2 | 1 | 1 | 2 | 1 | 3 | 7 | 6 | 7 | 7.5e-06 | 1 | 0.65 | 0.000096 | 0.14
14 | CDC27 | cell division cycle 27 homolog (S. cerevisiae) | 2565 | 189 | 0 | 0 | 5 | 0 | 0 | 0 | 5 | 5 | 5 | 8.8e-06 | 1 | 0.56 | 0.00011 | 0.15
15 | FAM35A | family with sequence similarity 35, member A | 2781 | 52 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 2 | 0.0039 | 0.01 | 0.13 | 0.00012 | 0.15
16 | PAXIP1 | PAX interacting (with transcription-activation domain) protein 1 | 3292 | 27 | 0 | 0 | 3 | 0 | 1 | 0 | 4 | 4 | 4 | 0.00046 | 1 | 0.008 | 0.00015 | 0.18
17 | PTTG1IP | pituitary tumor-transforming 1 interacting protein | 563 | 164 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 2 | 1 | 0.00044 | 0.037 | 1 | 0.00022 | 0.23
18 | OTOP1 | otopetrin 1 | 1861 | 50 | 0 | 0 | 4 | 0 | 0 | 0 | 4 | 4 | 3 | 0.00043 | 0.04 | 0.56 | 0.00027 | 0.28
19 | IL12RB2 | interleukin 12 receptor, beta 2 | 2649 | 20 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 1 | 0.0016 | 0.035 | 0.44 | 0.00039 | 0.37
20 | EPHA2 | EPH receptor A2 | 2995 | 72 | 0 | 0 | 2 | 1 | 0 | 1 | 4 | 4 | 4 | 0.00029 | 1 | 0.16 | 0.00059 | 0.54
21 | SMG1 | smg-1 homolog, phosphatidylinositol 3-kinase-related kinase (C. elegans) | 11234 | 42 | 0 | 0 | 4 | 0 | 0 | 0 | 4 | 4 | 3 | 0.057 | 0.0035 | 0.28 | 0.00088 | 0.76
22 | ARAF | v-raf murine sarcoma 3611 viral oncogene homolog | 1881 | 36 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 1 | 0.0088 | 0.01 | 0.062 | 0.00091 | 0.76
23 | NBN | nibrin | 2325 | 129 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 1 | 0.01 | 0.01 | 0.011 | 0.0011 | 0.83
24 | DNAH6 | dynein, axonemal, heavy chain 6 | 12781 | 489 | 0 | 0 | 2 | 0 | 0 | 1 | 3 | 3 | 3 | 0.0027 | 1 | 0.032 | 0.0011 | 0.83
25 | PRG4 | proteoglycan 4 | 4319 | 240 | 0 | 1 | 4 | 0 | 0 | 0 | 4 | 4 | 3 | 0.018 | 0.0053 | 0.96 | 0.0011 | 0.83
26 | MGA | MAX gene associated | 9290 | 14 | 0 | 0 | 2 | 0 | 1 | 0 | 3 | 3 | 3 | 0.0015 | 1 | 0.042 | 0.0014 | 0.96
27 | ZNF676 | zinc finger protein 676 | 1775 | 33 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 2 | 0.16 | 0.001 | 0.99 | 0.0015 | 1
28 | ELF4 | E74-like factor 4 (ets domain transcription factor) | 2020 | 31 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 2 | 2 | 0.00018 | 1 | 0.99 | 0.0018 | 1
29 | BCOR | BCL6 co-repressor | 5324 | 53 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 2 | 0.055 | 0.0031 | 0.93 | 0.0018 | 1
30 | BCL6B | B-cell CLL/lymphoma 6, member B (zinc finger protein) | 1472 | 203 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 1 | 0.022 | 0.01 | 0.73 | 0.0021 | 1
31 | AGAP6 | ArfGAP with GTPase domain, ankyrin repeat and PH domain 6 | 2089 | 20 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 1 | 0.024 | 0.01 | 0.16 | 0.0022 | 1
32 | SLC19A3 | solute carrier family 19, member 3 | 1511 | 1000 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 1 | 0.027 | 0.01 | 0.027 | 0.0025 | 1
33 | SMARCA5 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5 | 3251 | 90 | 0 | 0 | 1 | 1 | 1 | 0 | 3 | 3 | 3 | 0.0008 | 1 | 0.27 | 0.0026 | 1
34 | HTT | huntingtin | 9693 | 18 | 0 | 1 | 3 | 0 | 0 | 2 | 5 | 4 | 4 | 0.064 | 0.005 | 1 | 0.0031 | 1
35 | EIF4ENIF1 | eukaryotic translation initiation factor 4E nuclear import factor 1 | 3033 | 35 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 2 | 2 | 0.0019 | 1 | 0.098 | 0.0031 | 1

PBRM1

Figure S1. This figure depicts the distribution of mutations and mutation types across the PBRM1 significant gene.

HLA-B

Figure S2. This figure depicts the distribution of mutations and mutation types across the HLA-B significant gene.

FTH1

Figure S3. This figure depicts the distribution of mutations and mutation types across the FTH1 significant gene.

TP53

Figure S4. This figure depicts the distribution of mutations and mutation types across the TP53 significant gene.

ARID1A

Figure S5. This figure depicts the distribution of mutations and mutation types across the ARID1A significant gene.

DDHD1

Figure S6. This figure depicts the distribution of mutations and mutation types across the DDHD1 significant gene.

MUC2

Figure S7. This figure depicts the distribution of mutations and mutation types across the MUC2 significant gene.

IDH1

Figure S8. This figure depicts the distribution of mutations and mutation types across the IDH1 significant gene.

MUC21

Figure S9. This figure depicts the distribution of mutations and mutation types across the MUC21 significant gene.

CLIP4

Figure S10. This figure depicts the distribution of mutations and mutation types across the CLIP4 significant gene.

RUFY1

Figure S11. This figure depicts the distribution of mutations and mutation types across the RUFY1 significant gene.

Methods & Data
Methods

In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]

Download Results

In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.

- Analysis Results (MD5 checksum)

- Auxiliary Data (MD5 checksum)

- MAGE-TAB File (MD5 checksum)

References
[1] TCGA, Integrated genomic analyses of ovarian carcinoma, Nature 474:609 - 615 (2011)
Copyright © 2015 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle